Navamedic ASA (NAVA.OL) Aktuelle Nachrichten und Schlagzeilen zu Aktien – Yahoo Finanzen

Navamedic and Orion Corporation sign non-binding term sheet for Flexilev® in Europe

Navamedic ASA and Orion Corporation (“Orion”) today signed a non-binding term sheet for a license and supply agreement for Flexilev®, including the Orafid dispenser, throughout Europe, excluding Sweden, Norway, Denmark and Iceland, where Navamedic will market and sell the product. Flexilev® is a novel prescription treatment for Parkinson’s disease and was added to Navamedic’s product portfolio following the acquisition of Sensidose AB in May 2023.